Brawn Biotech Limited

Healthcare · Pharmaceuticals & Biotechnology

BSE: 530207
₹23.57
▲ 1.12 (4.99%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
36/100
Weak
Valuation
96/100
Undervalued
Momentum
86/100
Bullish

QVM read Cheap and turning up Quality Weak, Valuation Undervalued, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹7 Cr
PE (TTM)
8.2
Industry median 36.1 (152 companies)
Price to Book
1.6
PEG (TTM)
0.0
Institutions holding %
0.35%
FII + DII, latest filed period
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-5.0
Free Cash Flow
₹0 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-41.57%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
149.42%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
13.56%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-34.75%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
4.85%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.13
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.00
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
-1.41
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
2.53%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
2.54%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
-0.27%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
-0.66%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
0.61%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
-3.16%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.00)
  • No Return on equity is 15% or more (-3.2%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

2 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

4 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Fair Value Zone)
  • Yes Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
5.0%
Low 23.5700 · High 23.5700
1W return
9.6%
Low 21.3900 · High 23.5700
1M return
3.6%
Low 21.3900 · High 23.8000
52W return
-5.0%
Low 19.2500 · High 23.9500
Lifetime High ₹91.9000 (April 19, 2017)
Lifetime Low ₹3.7800 (June 21, 2013)

Full price history and technicals →

EMA & SMA

Bullish6
Bearish0
5D
22.5
10D
22.3
20D
22.4
50D
22.4
100D
21.7
200D
19.9

Delivery and volume

Day avg. delivery
99.9%
Week avg. delivery
100.0%
Month avg. delivery
99.2%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

23.57
Pivot
First resistance23.57
Second resistance23.57
Third resistance23.57
First support23.57
Second support23.57
Third support23.57
Day RSI56.8
Day MFI49.4
Day MACD-0.12
Day MACD signal-0.15

Beta

1M-1.24
3M-0.73
1Y-0.73
3Y0.09

Price change analysis

↑ 3.6%
Over 1 Month
LowHigh
21.3923.80
↓ -5.0%
Over 3 Months
LowHigh
19.2523.95
↓ -5.0%
Over 6 Months
LowHigh
19.2523.95
↓ -5.0%
Over 1 Year
LowHigh
19.2523.95
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 8.2 (own history: 7.6–8.6)
Fair Value Zone
Revenue (June 30, 2026)
₹6 Cr
Net profit (June 30, 2026)
₹0 Cr
Basic EPS (June 30, 2026)
₹0.5200

Ranks #179 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter52.94%
  • Mutual funds0.35%
  • Public46.71%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 52.94% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings were unchanged at 0.00% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings were unchanged at 0.35% in Jun 2026 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
20 Dec 2024 NAIMABBAS ANVARALI JAMANI Bulk Sell 2,000 22.5000 BSE
20 Dec 2024 NAIMABBAS ANVARALI JAMANI Bulk Buy 17,650 22.7600 BSE
6 Jan 2016 GUNMALA JAIN Bulk Sell 18,102 59.0000 BSE
9 Jun 2009 KALPANAAGRAWAL Bulk Sell 21,850 19.7700 BSE
29 May 2009 R K TULI Bulk Sell 15,200 34.6800 BSE
9 Sep 2005 KALPANA AGARWAL Bulk Buy 30,000 18.1600 BSE

All bulk and block deals →

Corporate Actions

Full history (1 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from BRAWN PHARMACEUTICALS LTD. to Brawn Biotech Limited

All corporate actions →

Corporate Announcements

All 5 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
29 Sep 2026 AGM/EGM Brawn Biotech Ltd - 530207 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
29 Sep 2026 AGM/EGM Brawn Biotech Ltd - 530207 - Proceedings Of 41St AGM
29 Sep 2026 AGM/EGM Brawn Biotech Ltd - 530207 - Shareholder Meeting / Postal Ballot-Outcome of AGM
29 Sep 2026 Company Update Brawn Biotech Ltd - 530207 - Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
28 Sep 2026 Insider Trading / SAST Brawn Biotech Ltd - 530207 - Closure of Trading Window

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.00)

Weaknesses

  • Low Return on Equity (-3.2%)
  • Thin net profit margin (2.5%)
  • Declining profit YoY (-34.7%)

Opportunities

  • PEG below 1 (0.04) -- earnings growth outpacing its own valuation
  • PE below 15 (8.2) relative to a typical growth business

Threats

  • Weak interest coverage (-1.4x) -- limited cushion against rising rates

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Brawn Biotech Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.